TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report report published on Wednesday, MarketBeat reports. The firm issued a buy rating and a $44.00 target price on the stock.

A number of other research analysts have also issued reports on PVLA. HC Wainwright restated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a report on Friday, January 10th. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Stock Up 6.3 %

NASDAQ PVLA opened at $14.76 on Wednesday. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The firm has a market capitalization of $165.61 million, a PE ratio of -1.22 and a beta of 0.68.

Insider Activity at Palvella Therapeutics

In related news, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were acquired at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.39% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.